Certificate in Cancer Immunotherapy Module 6: Oncolytic Viruses and Intralesional Therapy

Coming soon!

Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

This course, Module 6: Oncolytic Viruses and Intralesional Therapy, will cover the biological foundation and clinical implementation of intratumoral therapies and oncolytic viruses.


Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

Faculty

Brian Gastman, MD
Professor, Department of Surgery, School of Medicine
Member, Hematopoietic and Immune Cancer Biology Program, Case Comprehensive Cancer Center
Case Western Reserve University, Cleveland, OH
Department of Plastic Surgery
Cleveland Clinic Main Campus, Cleveland, OH

Ann Silk, MD, MS
Co-Director of the Merkel Cell Carcinoma Center of Excellence
Dana-Farber Cancer Institute, Boston, MA
 

Learning Objectives

Topic At the conclusion of this activity, the participant should be able to:

Basic Mechanisms of Oncolytic Viruses
and Intralesional Therapy

  • Describe the rationale for intralesional therapy as a strategy for modulating tumor cells and promoting immunity.
  • Distinguish the differences between oncolytic viruses and non-viral intralesional approaches.  
  • Classify the different viruses available for cancer immunotherapy and their advantages and disadvantages.
  • List approved oncolytic viruses and intralesional agents.
  • Describe the dual mechanism of action of oncolytic viruses in mediating anti-tumor immunity.
  • Identify how oncolytic viruses can deliver transgenes to promote anti-tumor activity.
  • Describe alternative delivery routes of administration for oncolytic viruses and other intralesional agents.

Patient Selection and Monitoring
for Oncolytic Virus Therapies and Intralesional Therapy

  • Identify eligible patients for oncolytic viruses and intralesional therapy.
  • Determine when oncolytic viruses and/or intralesional therapy should be considered in patient management.
  • Select appropriate tumors for injection of an oncolytic virus and/or intralesional therapy.
  • Determine the volume of oncolytic virus and/or intralesional agent for patient therapy.
  • Describe the process of injecting oncolytic viruses and/or intralesional treatments in patients with cancer.
  • Identify the role of interventional radiology in administration of intralesional treatments to deep and/or visceral tumors.
  • Apply appropriate injection site management following injection of intralesional agents.
  • Define the patterns of response with oncolytic viruses and other intralesional treatments.
  • Identify contraindications to oncolytic virus and/or intralesional therapy.
  • Outline the potential role for oncolytic viruses and intralesional therapy as part of combination regimens for patients with cancer.

Management of Oncolytic Virus and intralesional therapy Adverse Events

  • Identify the most common adverse events seen with oncolytic viruses and/or other intralesional treatments.
  • Prescribe appropriate intervention for managing common adverse events associated with oncolytic viruses and intralesional therapies.

Logistical and Biosafety Issues
Associated with Oncolytic Virus Therapy

  • Describe the biosafety issues associated with oncolytic virus administration.
  • Recognize the potential for bioshedding and contact transmission associated with oncolytic viruses.
  • Explain how to modify patient flow to optimize integration of oncolytic viruses and intralesional treatments into clinical practice.
  • Implement standard operating procedures for safe delivery of oncolytic viruses and intralesional treatments into clinical practice.


 


SITC Online Education Disclaimer

 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

 



Continuing Education Information

Date of CE Release:  To be announced
Date of CE Expiration: To be announced
Approximate Time to Complete:  90 minutes

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacist

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and SITC.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation  Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM for physicians, 1.50 contact hours for nurses, and 1.50 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

ABIM MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­6.2, 6.5)

All individuals in a position to control the content of CE are listed online. If their name is not listed below, they disclosed that they had no relevant financial relationships.
 

FIRST NAME

LAST NAME

RELATIONSHIP:COMMERCIAL INTEREST

To be updated before the launch of the module    


Method of Participation and Request for Credit
During the approved time period (to be announced) participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

  1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
  2. Under Pending Credit, click Request Credit for Certificate in Cancer Immunotherapy Module 6: Oncolytic Viruses and Intralesional Therapy.
  3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
  4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
  5. Click Process Credit.
  6. Your Certificate will be available to view in the Submitted Credit section.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1. Registration Survey
2. Certificate in Cancer Immunotherapy Module 6: Oncolytic Viruses and Intralesional Therapy

Next, to view the course, close this window and you will be taken to the course menu page. Once there, refresh the course menu page and select View Now for the last topic.

Individual topic purchase: Selected
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 1.50
Accreditation Council for Continuing Medical Education (non-MD/DO)
AMA PRA Category 1 Credit(s)™: 1.50
Certificate of Participation (No Credit)
Certificate of Participation: 0.00
Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 1.50
Accreditation Council for Pharmacy Education
Contact Hour: 1.50
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 1.50